Market Cap 1.85B
Revenue (ttm) 10.27B
Net Income (ttm) 157.00M
EPS (ttm) N/A
PE Ratio 1.28
Forward PE 1.23
Profit Margin 1.53%
Debt to Equity Ratio -19.19
Volume 3,176,700
Avg Vol 1,683,568
Day's Range N/A - N/A
Shares Out 373.81M
Stochastic %K 48%
Beta 0.40
Analysts Hold
Price Target $7.50

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. T...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 514 744 6792
Address:
2150 St. Elzéar Blvd. West, Laval, Canada
Coolhat1
Coolhat1 Jun. 5 at 4:32 AM
$BHC @SellSalix y block me on yahoo. I am a bag holder too 😪😪
0 · Reply
Coolhat1
Coolhat1 Jun. 5 at 3:24 AM
$BHC anyone still invested in this garbage I shorted at 6.20 pop after earning always short the pop till it reach’s zero
0 · Reply
ccledez
ccledez Jun. 3 at 8:33 PM
$BHC 👀👁️
0 · Reply
Bobberty
Bobberty Jun. 3 at 1:34 PM
$BHC and it's a small cap penny stock again!! Crazy to think this was once the largest company in Canada.
1 · Reply
brunoq14
brunoq14 Jun. 2 at 9:58 PM
$BHC There's a possibility that interest might develop in the larsucosterol trial, as it is a potentially lifesaving drug, and management views it as a platform drug for multiple indications. It might even put some life in the stock price. Still in the early stages.
0 · Reply
CgI86
CgI86 May. 28 at 6:49 AM
0 · Reply
truckersam
truckersam May. 28 at 2:56 AM
$BHC Somebody buy this POS already.
1 · Reply
Investor6
Investor6 May. 21 at 9:28 AM
$NXGL "May 19, 2026: Positive Clinical Study Data: NEXGEL reported results from a randomized, single-center IRB study on its hydrogel laser treatment patch for laser hair removal. The patch achieved a 95.6% reduction in plume concentration (p=0.0001) vs. control, plus greater hair reduction (37.2% vs. 26.7%) and lower pain scores (3.5 vs. 5.1). No adverse events, data published in Lasers in Surgery and Medicine. This addresses safety concerns around laser plume (airborne particles). CEO Adam Levy highlighted its potential as a low-cost safety solution amid growing regulations." After this study, NXGL should start selling in Europe and Asia by representatives there, like they do in Canada. The laser plume is a crucial issue, directly related with carcinogenesis, therefore, this is great news also for companies related with skin laser, like $INMD $LASE (thru its subsidiary CMS Laser), $BHC and potentially $APYX
0 · Reply
Vwill33
Vwill33 May. 20 at 5:39 PM
$BHC can we please get back to $8 so I can get out
1 · Reply
FibonacciTrader_
FibonacciTrader_ May. 20 at 2:18 PM
Reality check for hype traders $10K in these 2016 “hot” names today? Hardly what anyone imagined: $GPRO$1,130 $UAA$1,373 $PSKY$1,900 $BHC$2,026 $DDD$2,180 Hype can torch your capital over time. Always take profits, manage risk, and respect compounding — chasing narratives alone rarely wins the decade-long game. This is a setup to remind traders: paper gains are nice, but realized profits build accounts.
3 · Reply
Latest News on BHC
Bausch Health Companies Transcript: AGM 2026

May 19, 2026, 9:00 AM EDT - 16 days ago

Bausch Health Companies Transcript: AGM 2026


Bausch Health Companies Earnings Call Transcript: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 5 weeks ago

Bausch Health Companies Earnings Call Transcript: Q1 2026


Bausch Health Companies Slides: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 5 weeks ago

Bausch Health Companies Slides: Q1 2026


Bausch Health Companies Earnings release: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 5 weeks ago

Bausch Health Companies Earnings release: Q1 2026


Bausch Health Companies Quarterly report: Q1 2026

Apr 29, 2026, 5:00 PM EDT - 5 weeks ago

Bausch Health Companies Quarterly report: Q1 2026


Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c

2026-04-29T20:33:36.000Z - 5 weeks ago

Bausch Health reports Q1 non-GAAP EPS 78c, consensus 69c


BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Apr 29, 2026, 4:05 PM EDT - 5 weeks ago

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS


Bausch Health Companies Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Bausch Health Companies Proxy statement: Proxy filing


Bausch Health Companies Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Bausch Health Companies Proxy statement: Proxy filing


Bausch Health price target lowered to $7 from $8 at Barclays

2026-02-25T10:15:55.000Z - 3 months ago

Bausch Health price target lowered to $7 from $8 at Barclays


Bausch Health Companies Earnings Call Transcript: Q4 2025

Feb 18, 2026, 5:00 PM EST - 3 months ago

Bausch Health Companies Earnings Call Transcript: Q4 2025


Bausch Health Companies Annual report: Q4 2025

Feb 18, 2026, 5:00 PM EST - 3 months ago

Bausch Health Companies Annual report: Q4 2025


Bausch Health Companies Earnings release: Q4 2025

Feb 18, 2026, 5:00 PM EST - 3 months ago

Bausch Health Companies Earnings release: Q4 2025


Bausch Health Companies Slides: Q4 2025

Feb 18, 2026, 5:00 PM EST - 3 months ago

Bausch Health Companies Slides: Q4 2025


Bausch Health reports Q4 EPS (30c) vs. 25c a year ago

2026-02-18T21:21:45.000Z - 3 months ago

Bausch Health reports Q4 EPS (30c) vs. 25c a year ago


NY AG announces settlement with Lannett and Bausch Health

2026-02-02T19:40:25.000Z - 4 months ago

NY AG announces settlement with Lannett and Bausch Health


Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Jan 23, 2026, 7:45 AM EST - 4 months ago

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials


Bausch Health price target raised to $8 from $7 at Truist

2026-01-07T12:20:14.000Z - 5 months ago

Bausch Health price target raised to $8 from $7 at Truist


Bausch Health initiated with an Equal Weight at Barclays

2025-12-08T21:31:57.000Z - 6 months ago

Bausch Health initiated with an Equal Weight at Barclays


Bausch Health rises 14.8%

2025-12-01T17:00:16.000Z - 6 months ago

Bausch Health rises 14.8%


Bausch Health rises 11.3%

2025-12-01T15:05:36.000Z - 6 months ago

Bausch Health rises 11.3%


Bausch Health launches offers to exchange senior secured notes

2025-11-24T12:50:20.000Z - 6 months ago

Bausch Health launches offers to exchange senior secured notes


Bausch + Lomb to Hold Investor Day on Nov. 13

Nov 3, 2025, 4:30 PM EST - 7 months ago

Bausch + Lomb to Hold Investor Day on Nov. 13


Bausch Health Companies Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

Bausch Health Companies Earnings Call Transcript: Q3 2025


Bausch Health Companies Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

Bausch Health Companies Quarterly report: Q3 2025


Bausch Health Companies Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

Bausch Health Companies Earnings release: Q3 2025


Bausch Health Companies Slides: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

Bausch Health Companies Slides: Q3 2025


Bausch Health Announces Third Quarter 2025 Results

Oct 29, 2025, 4:05 PM EDT - 7 months ago

Bausch Health Announces Third Quarter 2025 Results


Bausch Health Companies Proxy statement: Proxy Filing

Aug 27, 2025, 8:00 AM EDT - 10 months ago

Bausch Health Companies Proxy statement: Proxy Filing


Bausch + Lomb board members resign after Icahn agreement ends

Aug 18, 2025, 5:48 PM EDT - 10 months ago

Bausch + Lomb board members resign after Icahn agreement ends


Bausch Health Companies Proxy statement: Proxy Filing

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Bausch Health Companies Proxy statement: Proxy Filing


Bausch Health Companies Earnings Call Transcript: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Earnings Call Transcript: Q2 2025


Bausch Health Companies Quarterly report: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Quarterly report: Q2 2025


Bausch Health Companies Earnings release: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Earnings release: Q2 2025


Bausch Health Companies Slides: Q2 2025

Jul 30, 2025, 5:00 PM EDT - 11 months ago

Bausch Health Companies Slides: Q2 2025


Bausch Health Announces Second Quarter 2025 Results

Jul 30, 2025, 4:05 PM EDT - 11 months ago

Bausch Health Announces Second Quarter 2025 Results


Coolhat1
Coolhat1 Jun. 5 at 4:32 AM
$BHC @SellSalix y block me on yahoo. I am a bag holder too 😪😪
0 · Reply
Coolhat1
Coolhat1 Jun. 5 at 3:24 AM
$BHC anyone still invested in this garbage I shorted at 6.20 pop after earning always short the pop till it reach’s zero
0 · Reply
ccledez
ccledez Jun. 3 at 8:33 PM
$BHC 👀👁️
0 · Reply
Bobberty
Bobberty Jun. 3 at 1:34 PM
$BHC and it's a small cap penny stock again!! Crazy to think this was once the largest company in Canada.
1 · Reply
brunoq14
brunoq14 Jun. 2 at 9:58 PM
$BHC There's a possibility that interest might develop in the larsucosterol trial, as it is a potentially lifesaving drug, and management views it as a platform drug for multiple indications. It might even put some life in the stock price. Still in the early stages.
0 · Reply
CgI86
CgI86 May. 28 at 6:49 AM
0 · Reply
truckersam
truckersam May. 28 at 2:56 AM
$BHC Somebody buy this POS already.
1 · Reply
Investor6
Investor6 May. 21 at 9:28 AM
$NXGL "May 19, 2026: Positive Clinical Study Data: NEXGEL reported results from a randomized, single-center IRB study on its hydrogel laser treatment patch for laser hair removal. The patch achieved a 95.6% reduction in plume concentration (p=0.0001) vs. control, plus greater hair reduction (37.2% vs. 26.7%) and lower pain scores (3.5 vs. 5.1). No adverse events, data published in Lasers in Surgery and Medicine. This addresses safety concerns around laser plume (airborne particles). CEO Adam Levy highlighted its potential as a low-cost safety solution amid growing regulations." After this study, NXGL should start selling in Europe and Asia by representatives there, like they do in Canada. The laser plume is a crucial issue, directly related with carcinogenesis, therefore, this is great news also for companies related with skin laser, like $INMD $LASE (thru its subsidiary CMS Laser), $BHC and potentially $APYX
0 · Reply
Vwill33
Vwill33 May. 20 at 5:39 PM
$BHC can we please get back to $8 so I can get out
1 · Reply
FibonacciTrader_
FibonacciTrader_ May. 20 at 2:18 PM
Reality check for hype traders $10K in these 2016 “hot” names today? Hardly what anyone imagined: $GPRO$1,130 $UAA$1,373 $PSKY$1,900 $BHC$2,026 $DDD$2,180 Hype can torch your capital over time. Always take profits, manage risk, and respect compounding — chasing narratives alone rarely wins the decade-long game. This is a setup to remind traders: paper gains are nice, but realized profits build accounts.
3 · Reply
AnthonyNicholas
AnthonyNicholas May. 19 at 4:00 PM
$BHC anyone listen to the call? What’s your take on?
1 · Reply
Rpate
Rpate May. 14 at 3:57 PM
$BHC BLCO showed negative free cash flow in Q1 2026 after two consecutive quarter of positive free cash flow. Now it may be possible BLCO can show negative free cash flow even after $7B revenue in 2028. Lot of noise about growth without positive free cash flow.
0 · Reply
Glene
Glene May. 14 at 12:30 AM
$BHC $DRRX how much are you figuring per share?
1 · Reply
bigbulldaddy
bigbulldaddy May. 13 at 11:02 PM
$BHC $DRRX Currently as of May Larsucosterol trial has 5/48 sites recruiting for 350 patient phase 3. Heads up to my people we are starting to move. Hope it’s quick. Good luck my LONG token holders… I did the math for myself: Assuming google is right I’m expecting… $288,000 at 500 million in sales $384,000 at 1 billion in sales Bausch is also looking at other R&D targets for Larsucosterol per info which we don’t get any money on… lol they literally called it REAHFIRM
1 · Reply
brunoq14
brunoq14 May. 13 at 2:51 AM
$BHC https://clinicaltrials.gov/study/NCT07428538 Three additional sites have begun recruiting for the larsucosterol trial, in Baltimore, Houston, and Richmond, joining Dallas and Charleston to make five in all. 48 sites are planned. Most recent update: 05/07/2026
0 · Reply
FU2
FU2 May. 11 at 10:44 PM
$BHC just total fuckery, heading to $5 again. Option traders are in full control. Hate these MM's to the core.
0 · Reply
truckersam
truckersam May. 11 at 8:27 PM
$BHC put 500,000 back in, we need the action 😁
0 · Reply
Bobberty
Bobberty May. 11 at 7:40 PM
$BHC and going sub $5 again. What a dumbass I am, should have kept it all in UNH. Oh well, get to enjoy the Canadian healthcare investment journey again.
0 · Reply
AnthonyNicholas
AnthonyNicholas May. 11 at 7:28 PM
$BHC what now why are we down so much today? 
0 · Reply
btradingwarehouse
btradingwarehouse May. 11 at 5:40 PM
$BHC ...2BULLS... ... ...Warriors ...We "lost" one of the most persistent bull (@SellSalix) ...His very classy update will be remembered ... ...Let's do quick reminder: ...You are NOT buying this beauty !!! ...Do NOT try to average unless you are trader (very good one) !!! ...You are NOT selling this beauty !!! ...Watch for BLCO ... Stay smart strong smile (if you can ?!)
0 · Reply
SellSalix
SellSalix May. 8 at 4:05 PM
$BHC it’s been a while, so I thought I would just update everyone. I sold this POS at a huge loss; about $500K. The opportunity cost on this probably adds another $500K (so, I effectively lost about a $1M). This is by far the worst investment I’ve ever made and it has scarred me for life. I did, however, end up buying long term calls at $5 and $10. If you are considering buying this stock, DON’T DO IT! Instead, buy call options that expire in a year or so. This is the only way to play this stock. I believe this will eventually re-rate once market comes to realize they will survive and monetize BLCO
8 · Reply
brunoq14
brunoq14 May. 7 at 11:13 AM
$BHC Anyone interested in the larsucosterol trial should check out the recent earnings presentation. In the question period, you will find a detailed description of how BHC is seeking to avoid the errors of the failed Durect trial, and why they are confident of success.
1 · Reply